SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry's TSX ticker is trending amid community discussion about its recent temporary removal from Stocktwits, sparking speculation of potential manipulation before earnings. Investors are also buzzing about the potential of BlackBerry's QNX technology and buyout rumors. The community anticipates a significant move following the upcoming earnings report.

MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.

MicroCloud Hologram Inc

MicroCloud Hologram Inc. is trending as investors discuss its potential in quantum computing, AI, and crypto, with some highlighting its large cash reserves. Community members are weighing bullish prospects of a short squeeze against concerns about share dilution. The stock is also gaining traction due to recent company news and speculation around potential partnerships.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates a major partnership announcement, with speculation focused on potential integrations with Ripple, traditional payroll providers, or even BlackRock. Discussions also highlight Zebec's real-world payment solutions and upcoming Uphold partnership, with many expressing excitement about the potential impact on the broader crypto ecosystem. Bullish sentiment is fueled by expectations of increased adoption and utility following recent private investment unlocks.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending due to a report linking Tylenol, a Kenvue product, to autism, sparking concerns and driving community discussion around potential lawsuits and the company's future. While some investors see this as a buying opportunity, others are wary, pointing to the potential for significant reputational damage and long-term sales impact. The community is actively debating the validity of the report, potential legal ramifications, and the company's response.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics is trending as discussions revolve around its potential in the robotics market, especially compared to competitors like Unitree. Bullish sentiment is fueled by the company's partnerships, including its China JV and Nvidia, and anticipation for its new robot announcement. Some investors are also weighing potential dilution and insider selling against the backdrop of overall positive momentum.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending as investors react to news of Jimmy Kimmel's show returning to ABC after a brief suspension, sparking heated debate. Community members are expressing strong opinions, with some calling for boycotts and subscription cancellations while others defend Disney's decision. The controversy highlights the complex intersection of politics, entertainment, and corporate decision-making within the broader media landscape.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending as investors discuss its potential for a short squeeze, highlighting its high short interest and increasing institutional ownership. Community members are pointing to the stock's technical setup, with some anticipating a breakout and surge towards higher price targets. The stock's association with AI and potential partnerships are also fueling positive sentiment.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance Holding Co. is trending due to a recent surge, fueled by commentary from a hedge fund manager touting its potential and comparing it to Shopify. The stock's volatility is sparking debate, with some highlighting the company's fundamentals and AI technology, while others point to its history, reverse splits, and potential for a short squeeze. Community members are actively discussing price targets, potential dilution, and the influence of the hedge fund manager's statements.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending downwards, with community members attributing the drop to a large shareholder selling off a significant portion of their stake and a board member resigning. Some traders are speculating about a potential link between Opendoor and Better, while others are concerned about the company's fundamentals and the recent executive commentary. Despite the negative sentiment, some investors view the dip as a buying opportunity, citing the new CEO and potential for future growth in the iBuying sector.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

Bollinger Innovations Inc

BINI is trending following a reverse stock split, leading to heated discussions about dilution, short selling, and the company's long-term viability. The community is expressing strong opinions about the stock's potential, with some calling it a scam while others anticipate a short squeeze. Overall, the conversation revolves around the impact of the reverse split and its potential consequences for both bulls and bears.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. President Donald Trump on Monday linked autism to both childhood vaccines and the use of Tylenol by pregnant women and children, claims that decades of scientific research have not supported.&nbsp;Meanwhile, Kenvue, the maker of Tylenol, rejected the claims. “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/trump-expected-link-autism-with-tylenol-experts-say-more-research-needed-2025-09-22/">report</a>, citing a company statement.&nbsp;Kenvue, which was spun off from Johnson &amp; Johnson in 2023, saw its shares fall 7.5% during Monday’s session to a record low before recovering 4.4% in extended trading.In a White House news conference, Trump repeatedly advised women and parents not to use the painkiller, saying, “Don’t take Tylenol. Fight like hell not to take it,” while acknowledging he was not a doctor.Standing alongside Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, Trump also called for a reexamination of vaccine schedules, urging separate measles, mumps, and rubella shots, and stating that the hepatitis B vaccine should not be administered until age 12, despite longstanding medical guidance recommending it within 24 hours of birth.&nbsp;Tylenol is Kenvue's largest brand, accounting for a mid-to-high single-digit percentage of total sales, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-autism-report-announcement-eb7c90c8?mod=hp_lead_pos1">noted</a>, citing Morningstar. Trump’s warning also comes as Kenvue continues to face litigation over acetaminophen, with hundreds of lawsuits alleging a link to autism or ADHD currently under appeal after a federal judge last year ruled the scientific evidence unreliable.Meanwhile, acetaminophen remains an important option for pregnant women, and vaccines have saved millions of lives, with UNICEF estimating at least 154 million lives preserved over the last 50 years.The Trump administration also announced steps to position leucovorin, a form of folic acid currently used in chemotherapy support, as a treatment for autism-related symptoms.&nbsp;The FDA approved a version of the drug from GSK and cited a review of 40 patients with cerebral folate deficiency, a rare metabolic disorder linked to neurological symptoms. Medicaid coverage for leucovorin will be extended to autism patients, with expectations that private insurers will follow.Researchers reiterated that there is no solid evidence that acetaminophen causes autism. A 2024 study using 2.5 million Swedish children found no causal relationship. In 2025, a review of 46 previous studies was done, which found an association, but it does not show cause and effect.&nbsp;Researchers advised that pregnant women who need acetaminophen should continue taking it at the lowest dose and for the shortest time. Bigger, randomized trials are still needed to determine leucovorin's potential.On Stocktwits, retail sentiment for Kenvue was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said the administration’s comments unfairly singled out Kenvue as if Tylenol were the only acetaminophen brand on the market, adding that people weren’t about to stop using the drug for everyday needs and calling the concerns overblown.<stembedurl>https://stocktwits.com/FatherofTrades/message/629593979</stembedurl>Another user said that they were buying every dip in Kenvue shares and planned to hold through the lawsuits and any eventual settlement.<stembedurl>https://stocktwits.com/StockCapture/message/629592908</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 18.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish

Investors weighed political scrutiny and unproven health claims as Tylenol’s maker faced renewed controversy, sparking volatility in Kenvue’s stock.

Equity

Shares of Kenvue slumped 6% on Monday afternoon following reports that the Trump administration is expected to unveil efforts exploring how Tylenol's active ingredient may be linked to autism.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.washingtonpost.com/health/2025/09/21/trump-autism-announcement-tylenol-leucovorin/">reported</a> on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol. They plan to warn pregnant women against using Tylenol early or unless they have a fever, sources told WSJ.Officials also intend to tout a drug called Leucovorin as a potential autism treatment, the report said. Leucovorin is a prescription medication typically used in cancer treatment to counter the harmful side effects of other drugs.White House press secretary Karoline Leavitt, however, urged people to await an announcement today from President Trump at a press briefing.“...before you jump to conclusions based on reports that the White House has not even confirmed, I would encourage everyone in this room to go into the four o'clock announcement with some critical thinking skills and with some open ears to actually listen to what the President and his team of outsiders have to say about this. And there will be a number of things that will be announced and discussed,” she said.Tylenol is made by McNeil Consumer Healthcare, a division of Kenvue, though other companies also sell acetaminophen-based products. It is widely used as a pain reliever, including by pregnant women.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KVUE">KVUE stock</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:574/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_2_12_39_PM_png_4b40cf5a25.webp" alt="KVUE's Sentiment Meter and Message Volume as of 2:12 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="574" height="61"><figcaption>KVUE's Sentiment Meter and Message Volume as of 2:12 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Trump, speaking at a memorial for conservative activist Charlie Kirk on Sunday, also touted a big announcement pertaining to autism. “Tomorrow we’re going to have one of the biggest announcement[s] … medically, I think, in the history of our country,” he said, as reported by WSJ. “I think you’re going to find it to be amazing. I think we found an answer to autism.”Earlier this month, it was reported that Kenvue Inc. reportedly <a href="https://stocktwits.com/news-articles/markets/equity/tylenol-kenvue-met-rfk-jr-to-keep-off-autism-list/chw8MshRdDV">met</a> with the U.S. Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller off a list of treatments causing autism.“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” Kenvue <a href="https://stocktwits.com/news-articles/markets/equity/kenvue-jnj-retail-traders-cautious-as-health-officials-plan-to-announce-tylenol-links-to-autism/chDQOxLR3cI">told</a> WSJ in a statement. Autism spectrum disorder (ASD) is a complex developmental condition involving persistent challenges with social communication, restricted interests, and repetitive behavior.KVUE stock is down by 20% this year and by about 25% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kenvue Shares Drop Ahead Of Trump’s ‘Biggest Announcement’ On Autism: Reports Say Administration To Link Tylenol With Risk Of Disease

The Wall Street Journal reported on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol.

The U.S. government is widely expected to link Tylenol to autism, advising pregnant women against its use, Monday, according to media reports. The development is keeping retail investors on the edge for its maker, Kenvue, and associated company Johnson &amp; Johnson, according to Stocktwits data.Tylenol is an acetaminophen-based over-the-counter medicine for reducing pain, allergies, cold, and fever. The popular tablets are produced, marketed, and sold by Kenvue, which spun off from J&amp;J in 2023,&nbsp;and rake in about $1 billion annually, a high-single-digit percentage of the firm’s total revenue,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.morningstar.com/stocks/kenvue-stock-tumbles-kennedys-pending-report-tylenol-autism">according</a> to a Morningstar analyst.U.S. officials&nbsp;are expected to hold a press conference on autism on Monday; in the run-up, President Donald Trump had said: "We think we found an answer to autism... There's obviously something really wrong, we think we know what that is."The Washington Post reported on the weekend that officials will promote the drug leucovorin as a potential autism treatment. Leucovorin is a prescription medication typically used in cancer treatment to counter the harmful side effects of other drugs.Earlier this month, the Wall Street Journal reported U.S. health officials' internal view regarding Tylenol. The news sent Kenvue's shares down 9.4% on Sept. 5. Kenvue said on Sunday that "independent, sound science" shows taking acetaminophen does not cause autism."We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers," the company said in a statement.Several Stocktwits users, on both Kenvue and J&amp;J&nbsp;streams, predicted steep declines for the stocks on Monday. Twenty-four-hour message volume on the tickers surging 300% and 150%, respectively.Retail sentiment for both KVUE and JNJ was ‘neutral’ at the time of writing, indicating significant levels of caution among traders ahead of Monday’s market open.<figure class="image"><img style="aspect-ratio:567/71;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_9_41_57_AM_png_e493de6988.webp" alt="Screenshot 2025-09-22 at 9.41.57 AM.png" width="567" height="71"><figcaption>KVUE sentiment and message volume as of September 21 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:571/73;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_9_42_37_AM_png_11ece70092.webp" alt="Screenshot 2025-09-22 at 9.42.37 AM.png" width="571" height="73"><figcaption>JNJ sentiment and message volume as of September 21 | Source: Stocktwits</figcaption></figure>"$JNJ 5-year chart looks like a heartbeat… she's gonna drop and flatline tomorrow," said a user.<stembedurl>https://stocktwits.com/TheDude5386/message/629455153</stembedurl>Another said: "$KVUE could be a buying opportunity if we see an overreaction."<stembedurl>https://stocktwits.com/Sigh_why/message/629453593</stembedurl>Kenvue's main brands include Tylenol, Motrin, Listerine, Neutrogena, Aveeno, and Band-Aid.<a href="https://stocktwits.com/symbol/KVUE">Kenvue shares</a> are down 14.1% year-to-date;&nbsp;<a href="https://stocktwits.com/symbol/JNJ">J&amp;J stock</a> is up 22%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-confirms-news-corp-s-murdochs-larry-ellison-michael-dell-lining-up-to-take-over-tik-tok-us/chDQBrbR3cR">Trump Confirms News Corp’s Murdochs, Larry Ellison, Michael Dell Lining Up To Take Over TikTok US</a>

Pain medications, which contain acetaminophen, are shown on April 14, 2015 in Chicago, Illinois. (Photo Illustration by Scott Olson/Getty Images)

Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism

Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue.

Top Wide-Moat Stocks Worth a Look for Sustainable Growth 

MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.

Tylenol maker Kenvue Inc. (KVUE) reportedly met with the U.S. Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller off a list of treatments causing autism.According to a Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-12/kenvue-met-with-rfk-jr-in-bid-to-keep-tylenol-off-autism-list">report</a>, Kenvue confirmed the meeting with RFK Jr., maintaining that acetaminophen, the active ingredient in Tylenol, does not cause autism.<a href="https://stocktwits.com/symbol/KVUE">Kenvue’s shares</a> were up 1.24% in Friday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory.Kenvue said in an emailed statement to Bloomberg that it engaged with the Health Secretary in a “scientific exchange” as it relates to the safety of its products. “We continue to believe that taking acetaminophen does not cause autism, and global health regulators, independent public health organizations, and medical professionals agree,” the company said, adding that acetaminophen is one of the most studied medications in history.Tylenol is a part of Kenvue’s self-care segment, which accounted for more than 40% of the company’s revenue in the second quarter (Q2). The company’s organic sales fell 4.2% during the quarter, which was due to “weak allergy and sun seasons in North America, trade inventory fluctuations in certain customers, and changes in shipment timing versus last year in China,” according to a statement from Kenvue.Last week, a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal noted the Department of Health and Human Services could link autism to the use of Tylenol in pregnancy. The HHS report is expected to be issued this month, it added.<a href="https://stocktwits.com/symbol/KVUE">KVUE stock</a> is down 11% year-to-date and 17% in the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-fed-rate-cuts-through-january/chw8AhGRdDi">Morgan Stanley Reportedly Expects 4 Rate Cuts Through January, Says Fed Will Aim To Arrive At Neutral Rates ‘More Decisively’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kenvue company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Tylenol Maker Kenvue Met With RFK Jr. In A Bid To Keep OTC Painkiller Off Autism List: Report

According to a Bloomberg report, Kenvue confirmed the meeting with RFK Jr., maintaining that acetaminophen, the active ingredient in Tylenol, does not cause autism.

Bank of America stated that Kenvue (KVUE) is expected to be viewed as a “particularly attractive entry point” after the recent pullback in its stock following media reports that surfaced that Health Secretary Robert F. Kennedy Jr. intends to link prenatal use of its Tylenol drug to autism.Analyst Anna Lizzul said that the company's new CEO and CFO took the opportunity in August to reset expectations at earnings and sees its lowered 2025 guidance as "achievable," according to TheFly.Shares of <a href="https://stocktwits.com/symbol/KVUE">Kenvue</a> closed down 9.3% on Friday. Bank of America noted that given the current valuation discount to the average of household and personal care peers, the firm reiterates its ‘Buy’ rating and $25 price target as it sees a widening discount offering an attractive entry point.Retail sentiment on Kenvue dipped to ‘bullish’ from ‘extremely bullish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:807/107;" src="https://news.stocktwits-cdn.com/KVUE_sentiment_png_2b6f08c92e.webp" alt="KVUE sentiment.png" width="807" height="107"><figcaption>KVUE sentiment and message volume September 8, 2025, as of 8:30 am ET | Source: Stocktwits</figcaption></figure>Evercore ISI lowered its price target on Kenvue to $23 from $25 and maintained an ‘In Line’ rating, reflecting lower peer valuations and the premium Tylenol commands within Kenvue's portfolio. The firm noted that the recent selloff in shares "might be overdone" when considering the lack of a proven causal link between Tylenol's active ingredient and neurodevelopmental disorders.According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal, in an upcoming Health Department report, there would be findings expected to link autism risk to low folate levels and Tylenol use during pregnancy.&nbsp;Despite headline risks, a lack of definitive evidence linking Acetaminophen, the active ingredient in Tylenol, to autism may suggest limited long-term impact. Still, legal uncertainties could delay strategic moves, Evercore added.&nbsp;&nbsp;Kenvue shares have declined nearly 13% this year and approximately 20% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/this-sportswear-giant-got-added-to-jefferies-franchise-picks-list/chwWxLeRdrc">This Sportswear Giant Got Added To Jefferies’ Franchise Picks List – Find Out More</a>

Kenvue Seen As Attractive Buy By BofA After Stock Dip Following Report On Tylenol Autism Link

Evercore said that the recent selloff in shares "might be overdone" when considering the lack of a proven causal link between Tylenol's active ingredient and neurodevelopmental disorders.

Kenvue Seen As Attractive Buy By BofA After Stock Dip

Tylenol maker Kenvue (KVUE) dropped to a one-year low in afternoon trade on Friday after reports surfaced that Health Secretary Robert F. Kennedy Jr. intends to link prenatal use of the drug to autism.<a href="http://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> tumbled more than&nbsp;13%&nbsp;to&nbsp;$17.77, its lowest level since&nbsp;July 2024. On Stocktwits, retail sentiment around the company fell into ‘bearish’ territory from ‘neutral’ over the past day.&nbsp;Friday’s drop brings Kenvue’s year-to-date loss to over 17%. The stock has fallen 21% over the past 12 months.According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal, the Department of Health and Human Services (HHS) is likely to release its findings later this month. The upcoming Health Department report is expected to link autism risk to low folate levels and Tylenol use during pregnancy, people familiar with the matter told the publication.Tylenol is made by McNeil Consumer Healthcare, a division of Kenvue, though other companies also sell acetaminophen-based products. The active ingredient in Tylenol is acetaminophen, which is widely used as a pain reliever, including by pregnant women.&nbsp;The report said that research on its impact during pregnancy has produced mixed results. It cited that the American College of Obstetricians and Gynecologists found Tylenol to be safe for use during pregnancy. However, it advises women to consult with their doctors before taking any medication.Kennedy, meanwhile, has long promised to reveal the cause of autism. “By September, we will know what has caused the autism epidemic,” he&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bbc.com/news/articles/cj0z9nmzvdlo">said</a> during an April cabinet meeting with President Donald Trump.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bessent-says-fed-must-change-course-to-preserve-independence/chwI13sRdqQ">Bessent Reportedly Says Fed Must Change Course To Preserve Independence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tylenol, which contains acetaminophen, is offered for sale at a drug store on April 14, 2015 in Chicago, Illinois. (Photo by Scott Olson/Getty Images)

Kenvue Stock Hits One-Year Low After Report Says HHS Will Link Tylenol Use In Pregnancy To Autism Risk

According to a report by The Wall Street Journal, the Department of Health and Human Services is likely to release its findings later this month. 

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.

Kenvue (KVUE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kenvue (KVUE) Q2 Earnings Top Estimates

Kenvue (KVUE) delivered earnings and revenue surprises of +3.57% and -0.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

KVUE
Kenvue Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KVUE News

KVUE Kenvue Inc